Analysis of the Biofield Energy Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Based Assay

Journal: Advances in Complementary & Alternative medicine PDF  Web

Published: July 12, 2019 Volume: 4 Issue: 4

DOI: 10.31031/ACAM.2019.04.000599 ISSN: 2637-7802

Authors: Aguilar Tiraboschi MI, Kumar Trivedi M, Alice Branton, Dahryn Trivedi, Gopal Nayak, Charan Mondal S and Snehasis Jana

Citation: Aguilar Tiraboschi MI, Kumar Trivedi M, Alice Branton, Dahryn Trivedi, Gopal Nayak. Analysis of the Biofield Energy Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Based Assay. Adv Complement Alt Med. 4(5). ACAM.000598.2019.

  • 8 Views
  • Downloads

Abstract

Vital organs dysfunction is one of the major concerns now-a-day, which results in high mortality rate in health care centers. Thus, growth and normal functioning of the vital organs is the major concern for better health. The aim of this study was to investigate the impact of the Biofield Energy on the test formulation and the cell line media for the function of vital organs such as bones, heart, liver, lungs, and brain using cell-based assays. Different organ-based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Maria Isabel Aguilar Tiraboschi, Uruguay and were labeled as the Biofield Energy Treated (BT) test formulation. Cell viability data suggested that the test formulation was safe and non-toxic in nature in the tested cell lines. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 23.7% (at 25.5μg/mL), 54.1% (at 10μg/mL), and 81.6% (at 63.75μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75μg/mL), 20.2% (at 63.75μg/mL), and 43.9% (at 10μg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 121.9% (at 1μg/mL), 416% (at 25.5μg/mL), and 323% (at 25.5μg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 78.2% at 50μg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 67.5% at 50μg/mL in the BT-Med + UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 26.6% (at 25.5μg/mL), 37.9% (at 10μg/mL), and 76.5% (at 25.5μg/mL) in the UT-Med + BT-TI, BTMed + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 21.1% (at 10μg/mL), 93.9% (at 63.75μg/mL), and 51.4% (at 63.75μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 57.2% (at 25.5μg/mL), 176.9% (at 10μg/mL), and 184.2% (at 10μg/mL) in the UT-Med + BTTI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 34.8% (at 63.75μg/mL), 65.4% (at 63.75μg/mL), and 398.7% (at 1μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med+BT-TI groups, respectively compared to the untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 207.9% (at 0.1μg/mL), 37.1% (at 10μg/mL), and 141% (at 10μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The novel proprietary Biofield Energy Treated test formulation was found safe and non-toxic based on MTT cell viability assay in all the six tested cells. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 23.7% (at 25.5μg/mL), 54.1% (at 10μg/mL), and 81.6% (at 63.75μg/mL) in the UTMed + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability by 53.4% (at 63.75μg/mL), 20.2% (at 63.75μg/mL), and 43.9% (at 10μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Similarly, the test formulation in A549 cells showed maximum restoration of cell viability by 121.9% (at 1μg/mL), 416% (at 25.5μg/mL), and 323% (at 25.5μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells showed significantly increased ALP activity by 77.6% and 78.2% in the UT-Med + BT-TI and BT-Med + BT-TI groups respectively, at 50μg/mL as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells with maximum cellular protection at 50μg/mL by 62.7%, 67.5%, and 36.3% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. LDH data was presented in terms of increased percentage cellular protection data, which suggested significant decreased activity, which showed maximum cellular protection by 26.6% (at 25.5μg/mL), 37.9% (at 10μg/mL), and 76.5% (at 25.5μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALT activity was studied and data showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 21.1% (at 10μg/mL), 93.9% (at 63.75μg/mL), and 51.4% (at 63.75μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 57.2% (at 25.5μg/mL), 176.9% (at 10g/mL), and 184.2% (at 10μg/ mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 34.8% (at 63.75μg/mL), 65.4% (at 63.75μg/mL), and 398.7% (at 1μg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 207.9%, 122.7%, and 203.5% in the UT-Med + BT-TI group at 0.1, 1, and 10μg/mL respectively, while 37.1% increased RQ of VDR at 10μg/mL in the BT-Med + UT-TI group, and increased RQ of VDR by 78%, 122.7%, and 141% at 0.1, 1, and 10μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Thus, Biofield Energy Treatment (The Trivedi Effect®) can be used for improving overall health such as significant role in cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.